Cargando…
Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson’s disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649055/ https://www.ncbi.nlm.nih.gov/pubmed/29052536 http://dx.doi.org/10.1186/s13073-017-0483-4 |